Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 09:48:02 2024-05-13 am EDT			5-day change	1st Jan Change
4.255 ^EUR	+1.31%		+38.60%	-36.49%

May. 06	Carmat: progress in ongoing clinical study	CF
May. 06	CARMAT Continues to Build on Its Momentum in the EFICAS Study	CI

CARMAT Appoints Professor Christian Latrémouille as Director of Surgical Affairs

February 01, 2021 at 01:00 am EST

CARMAT announced the appointment of Professor Christian Latrémouille as Director of Surgical Affairs. Before joining CARMAT, Christian was, since 2017, Head of the Cardiovascular Surgery Department at the Georges Pompidou European Hospital in Paris.

Latest news about CARMAT

Carmat: progress in ongoing clinical study	May. 06	CF
CARMAT Continues to Build on Its Momentum in the EFICAS Study	May. 06	CI
Carmat SA Reiterates Sales Guidance for the Year 2024	May. 06	CI
Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Carmat: final agreement with creditors	Mar. 25	CF
Carmat Secures Two-year Extensions for Bank Loans	Mar. 25	MT
CARMAT Announces a Final Agreement with All Its Financial Creditors on New Repayment Terms for Its Bank Loans	Mar. 22	CI
Carmat: up sharply, broker upgrades to 'buy	Feb. 01	CF
CARMAT : Invest Securities upgrades to 'buy'.	Feb. 01	CF
Oddo BHF Keeps Carmat at Neutral, Cuts PT	Jan. 29	MT
France’s Carmat Secures EUR17 Million via Capital Raise; Shares Fall	Jan. 29	MT
CARMAT : price target lowered by Oddo BHF	Jan. 29	CF
Carmat: capital increase completed	Jan. 29	CF
Carmat SA announced that it has received ?16.5186 million in funding	Jan. 28	CI
CARMAT : Invest Securities advises to subscribe	Jan. 18	CF
Transcript : Carmat SA - Special Call	Jan. 17
Carmat: launches a capital increase	Jan. 17	CF
Carmat SA announced that it expects to receive ?15.000002 million in funding	Jan. 16	CI
Carmat: has passed the 50-implant milestone	Jan. 15	CF
Artificial heart maker Carmat to launch capital increase soon	Jan. 15	RE
Carmat Sa Provides Sales Guidance for the Year 2024	Jan. 15	CI
Carmat: conditional agreement in principle with the EIB	Jan. 12	CF
Carmat Secures In-principle Extension for European Investment Bank Loan	Jan. 12	MT
Carmat SA Announces Conditional Agreement in Principle with the EIB on New Loan Repayment Terms	Jan. 12	CI
CAC40: modest rise in non-existent volumes	Dec. 29	CF

Chart CARMAT

Duration

Period

More charts

Company Profile

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-15 - Gilbert Dupont Société Générale MidCap Forum

More about the company

Income Statement Evolution

More financial data

Ratings for CARMAT

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.2 EUR

Average target price

13.52 EUR

Spread / Average Target

+222.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
CARMAT	-36.49%	112M
STRYKER CORPORATION	+9.89%	126B
SMITH & NEPHEW PLC	-6.35%	10.96B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+2.52%	8.97B
GLAUKOS CORPORATION	+38.57%	5.56B
INSPIRE MEDICAL SYSTEMS, INC.	-20.07%	4.99B
AXONICS, INC.	+8.26%	3.44B
ENOVIS CORPORATION	-8.53%	2.8B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-7.52%	2.18B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-3.00%	2.16B

Medical Devices & Implants